This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
Truly a LANDMARK trial. The investigators went to prove that lanthanum is superior to calcium for phosphate binding. What they found will surprise no one.
Join us for the first edition of the #NephTrials chat. Let’s take a deep dive into pragmatic trials, and take a specific example - the Phosphate trial, to anchor the discussion.
First chat of 2019 - showcasing again the honest brokers of nephrology trials with another negative trial. Also note we will be having a NephJC Asia chat starting this week!